We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A whiff of desperation

16 February 2011 By Pierre Briancon

The French pharma group has upped its cash offer for the U.S. biotech, and will pay a further $3.8 bln if certain milestones are met, taking the total premium to over 60 pct. After six months of talks, the upscaled bid shows just how badly Sanofi needs to repair its pipeline.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)